Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
39.18
-1.87 (-4.56%)
Feb 21, 2025, 4:00 PM EST - Market closed
Veracyte Employees
Veracyte had 815 employees as of December 31, 2023. The number of employees increased by 28 or 3.56% compared to the previous year.
Employees
815
Change (1Y)
28
Growth (1Y)
3.56%
Revenue / Employee
$521,879
Profits / Employee
-$11,372
Market Cap
3.04B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
VCYT News
- 2 days ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 8 days ago - New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research - Business Wire
- 11 days ago - Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium - Business Wire
- 17 days ago - New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer - Business Wire
- 17 days ago - Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025 - Business Wire
- 2 months ago - Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines - Business Wire
- 3 months ago - Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Veracyte Announces Third Quarter 2024 Financial Results - Business Wire